Bethyl is now a part of Fortis Life Sciences. Learn more.

Immuno-Oncology

Jump to antibodies.

Highly validated immune marker and checkpoint antibodies to accelerate tumor microenvironment research.

Immuno-oncology has rapidly transformed how we treat many types of cancer

Immuno-oncology has transformed how we treat many cancer types and provided hope for patients who receive advanced disease diagnoses. Unlike traditional cancer therapies that target tumor cells, immunotherapies stimulate the body’s immune system to eradicate tumor cells. Characterizing the types of immune cells present in the tumor microenvironment and profiling novel immune checkpoints are critical to advancing the field and developing novel immune therapies.

 

The relationship between a tumor and its microenvironment is fundamental to how cancer overrides normal cellular processes to proliferate. Recently, the most exciting therapies have involved clearing the immunosuppressive signals within the tumor using checkpoint inhibitors*. Successful inhibition of the PD-1 and CTLA-4 checkpoint pathways has revolutionized treatment, while discovering other receptor systems such as Tim-3, Lag-3, and OX40 has expanded the possibility of new checkpoint inhibitors.

Ongoing research in this field relies on dependable assay tools, such as antibodies that produce high quality, verifiable data in routine immuno-oncology applications. Browse an extensive catalog of rigorously validated recombinant antibodies for identifying immune-cell and tumor markers, T-cell markers and immune checkpoints. Bethyl antibodies are manufactured on-site and guaranteed to work in the intended application, including multiplex assay platforms.

 

 Keep Exploring:

White Papers & Tech Notes

Bringing the Tumor Microenvironment into Focus Multiplex white paper - Download Now

eBooks

Antibody Detection for Cancer Research
Download Now

Posters

Tumor Infiltrating Lymphocytes
Download Now



Immune Checkpoints

Tumors suppress immune responses by the activation of negative signaling pathways termed immune checkpoints or co-inhibitory pathways. The ability of T-cells to mount an effective response is also dependent the presence of co-stimulatory signaling. The characterization of the repertoire of inhibitory and stimulatory molecules can help determine the type of immunotherapy which will generate the most effective patient response.

 

Product
Specifications
Ordering Information
Human
WB
residues 71-254 (ECD)
Human, Mouse
WB, IP, IHC, ICC, IHC-IF, F
between 500 to 534 (C-term)
Human
WB, IP, IHC, ICC, F
residues 29-465 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
residues 30-282 (ECD)
Human
WB, IP, IHC, ICC
residues 24-189 (ECD)
Human
WB, IP, IHC, ICC
residues 21-187 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
between 227 and 277 (C-term)
Human
WB, IHC, ICC, IHC-IF
residues 27-552 (ECD)
Human
WB, IP, IHC, ICC
residues 29-502 (ECD)
Human
WB, IP, IHC, ICC
residues 19-229 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
between 191 and 241 (C-term)
Human
WB, IHC, ICC
residues 39-200 (ECD)
Human
WB, IHC, ICC, IHC-IF
residues 1-403 (full length)
Human
WB, IP
residues 1-403 (full length)
Human
WB, IP, IHC, ICC, IHC-IF, mIF
between 500 and 525 (C-term)
Human
WB, IP, IHC, ICC, IHC-IF
residues 23-450 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
residues 29-216 (ECD)
Human
IHC
residues 24-164 (ECD)
Human
WB, IP, IHC, IHC-IF, ICC-IF, mIF
between 250 to 290 (C-term)
Human
WB, IHC, IHC-IF
between 194 and 244 (C-term)
Human
WB, IHC, ICC, IHC-IF
residues 22-201 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF, F
between 250 and 311 (C-term)
Human
WB
Between 350 and 400
Human
IP, IHC
Between 484 and 534
Human
WB
Between 50 and 100
Human
WB, IP
Between 286 and 336
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-044 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-020 and A700-034
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-021 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A700-015, A700-027 and A700-034

Immune Cells & Tumor Markers

The tumor microenvironment contains normal cells, tumor cells, lymphocytes, and blood vessels. The identification and interaction of these tumor microenvironment constituents aids in diagnostics, treatment and response measures.

 

Product
Specifications
Ordering Information
Human
WB
residues 71-254 (ECD)
Human
WB, IP, IHC, ICC
between 798 and 848 (C-term)
Human, Mouse
WB, IHC, ICC
between 1 and 50
Human
WB, IP, IHC, ICC, IHC-IF
residues 1-322 (FL)
Human, Mouse
WB, IP, IHC, ICC, IHC-IF, F
between 500 to 534 (C-term)
Human
WB, IP, IHC, ICC, F
residues 29-465 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
residues 30-282 (ECD)
Human, Mouse
WB, IP, IHC, ICC
between 250 and 300
Human
WB, IP, IHC, ICC
residues 17-334 (ECD)
Human
WB, IHC, ICC
residues 112-355 (ECD)
Human
WB, IHC, ICC
between 350 and 400
Human
WB, IP, IHC, ICC
residues 24-189 (ECD)
Human
IHC
between 850 and 900
Human
WB, IHC, ICC
residues 21-291 (ECD)
Human
WB, IP, IHC, ICC
between 1406 and 1456 (C-term)
Human
WB, IP, IHC, IHC-IF, F
between 150 to 164 (C-term)
Human
WB, IP, IHC, ICC
residues 21-187 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
residues 19-385 (ECD)
Human
WB, IP, IHC, ICC
residues 28-601 (ECD)
Human
WB, IP, IHC
between 314 and 364 (C-term)
Human
WB, IP, IHC, ICC
residues 43-300 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF, F, mIF
between 157 and 207
Human
WB, IP, IHC, mIF
residues 26-397 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
between 227 and 277 (C-term)
Human, Mouse
WB, IP, IHC, ICC, F
between 700 and 742 (C-term)
Human
WB, IP, IHC, ICC, IHC-IF, F
between 1250 to 1306 (C-term)
Human
WB, IHC, ICC
residues 19-142 (ECD)
Human
WB, IHC, ICC, IHC-IF
residues 27-552 (ECD)
Human
WB, IHC, IHC-IF, mIF
between 185 and 235 (C-term)
Human
WB, IHC
residues 22-180 (ECD)
Human
WB, IP, ICC
residues 31-245 (ECD)
Human
WB, IP, IHC, ICC
between 300 to 329
Human
WB, IP, IHC, ICC
residues 29-502 (ECD)
Human, Mouse
WB, IP, IHC, ICC
between 125 and 175
Human
WB, IP, IHC, ICC
residues 19-229 (ECD)
Human
WB, IP, IHC, ICC
between 125 and 175
Human
WB, IP, IHC, ICC, IHC-IF, mIF
between 275 and 325
Human, Mouse
WB, IP, IHC, ICC
between 150 and 200
Human
WB, IP, IHC, ICC, IHC-IF
between 191 and 241 (C-term)
Human
WB, IHC, ICC, IHC-IF, mIF
residues 19-247 (mature protein)
Human
WB, IHC, ICC
residues 39-200 (ECD)
Human
WB, IHC, ICC, IHC-IF
residues 1-403 (full length)
Human
WB, IP
residues 1-403 (full length)
Human
WB, IP, IHC, ICC, F
between 250 and 300
Human, Mouse
WB, IP, IHC, ICC, F
surrounding serine 824
Human
IHC, ICC, IHC-IF, ICC-IF, F, mIF
between 1200 and 1250
Human
WB, IP, IHC, ICC, IHC-IF, mIF
between 500 and 525 (C-term)
Human
WB, IP, IHC, ICC, IHC-IF
residues 23-450 (ECD)
Human
WB, IHC, ICC, IHC-IF
between 50 and 100
Human
WB, IP, IHC, ICC, IHC-IF
residues 29-216 (ECD)
Human, Mouse
WB, IP, IHC, ICC, IHC-IF
residues 1-293
Human
WB, IHC, ICC, IHC-IF
between 225 and 261 (C-term)
Human
IHC
residues 24-164 (ECD)
Human
WB, IP, IHC, IHC-IF, ICC-IF, mIF
between 250 to 290 (C-term)
Human, Mouse
WB, IP, IHC, ICC-IF
surrounding serine 824
Human
WB, IHC, ICC, IHC-IF
residues 28-329 (ECD)
Human
WB, IP, IHC, ICC
between 1 and 50
Human
WB, IP
between 200 and 250
Human, Mouse
WB, IP, IHC, ICC
between 1 and 50
Human, Mouse
WB, IP, IHC, ICC, mIF
between 416 and 466 (C-term)
Human, Mouse
WB, IP, IHC, ICC
between 744 and 794 (C-term)
Human
WB, IHC, IHC-IF
between 194 and 244 (C-term)
Human
WB, IHC, ICC, IHC-IF
residues 22-201 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF, F
between 250 and 311 (C-term)
Human
WB
Between 350 and 400
Human
IP, IHC
Between 484 and 534
Human, Mouse
WB, IP, IHC
between 276 and 326
Human, Mouse
IHC
Between 276 and 326
Human
WB
Between 506 and 556
Human
WB, IHC, IHC-IF, F, mIF
Human tonsil B cells
Human
IP
Between 75 and 125
Human
WB, IP
Between 114 and 164
Human
WB, IP
Between 114 and 164
Human
WB
Between 50 and 100
Human
IHC
Between 700 and C-term
Human
WB, IP, IHC
Between 157 and 207
Human, Mouse
WB, IP, IHC
Between 692 and 742
Human
WB, IP, IHC, ICC-IF
Between 1254 and 1304
Human
WB, IHC, ICC, IHC-IF, mIF
Cultured T-cells from an IL-2-dependent T-cell line (CA1)
Human
IHC, IHC-IF, F, mIF
Lysosomal fraction of human lung macrophages
Human
WB, IHC, ICC
human SU-DHL-4 lymphoma cells
Human
IHC, IHC-IF, F
A 13 amino acid synthetic peptide from the C-terminal cytoplasmic domain of alpha chain of human CD8 molecule
Mouse
WB
between 150 and 200
Human
IHC, IHC-IF, ICC-IF, mIF
Human epidermal callus
Human
WB, IP
Between 286 and 336
Human
WB, IHC
between 150 and 200
Human
WB, IHC, ICC, IHC-IF
Activated human peripheral blood mononuclear cells
Mouse
WB, IP
between 200 and 250
Mouse
IP
between 250 and 300
Mouse
WB, IP
between 300 and 329
Human, Mouse
WB, IP, IHC, ICC
between 1 and 50
Human, Mouse
WB, IP, IHC
between 650 and 700
Human
WB, IP, IHC
Between 1 and 50
Mouse
WB, IP
Between 175 and 225
Mouse
WB, IP
Between 550 and 600
Human
IHC, ICC-IF
Between 1 and 50
Mouse
IHC
Between 1650 and 1700
Human
IHC
Between 1800 and 1850
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-044 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-044 and A500-017A
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-018A and A500-017A
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-020 and A700-034
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-021 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-022, A700-044, A500-019A, A700-021 and A700-080
Human
IHC-IF, mIF
Includes: 1 each of A700-044, A500-019A, A500-020A, A700-015 and A700-034
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A700-015, A700-027 and A700-034
Human
IP
between 1 and 50
Human, Mouse
WB, IP, IHC
Between 1639 and 1689
Human, Mouse
WB, IP, IHC, F
between 75 and 125
Human, Mouse
WB, IP, IHC, IHC-IF
between 225 and C-term
Human, Mouse
IHC, IHC-IF
Between 225 and C-term
Human, Mouse
WB, IP, IHC, ICC
recombinant rat PCNA
Human, Mouse
WB, IP, IHC, ICC, ICC-IF
surrounding serine 824
Mouse
WB
surrounding serine 824
Human
ICC-IF
Surrounding serine 824
Human
IHC
Surrounding tyrosine 211
Human
WB, IP
Between 1 and 50
Human, Mouse
WB, IP, IHC, ICC, IHC-IF
between 416 and 466
Human
WB, IP, IHC
between 744 and 794

T-Cell Markers

The ability of the immune system to respond to cancer is dependent on T-cells specific for tumor-associated antigens. Both immune related cells and tumor cells can influence the activation state of T-cells. The ability to phenotype activation status and sub-categories of T-cells present in the tumor microenvironment is important for predicting immune response towards the tumor.

 

Product
Specifications
Ordering Information
Human
WB, IP, IHC, ICC
between 798 and 848 (C-term)
Human, Mouse
WB, IP, IHC, ICC
between 250 and 300
Human
WB, IP, IHC, IHC-IF, F
between 150 to 164 (C-term)
Human
WB, IP, IHC, ICC
residues 21-187 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF, F, mIF
between 157 and 207
Human
WB, IP, IHC, mIF
residues 26-397 (ECD)
Human
WB, IHC, IHC-IF, mIF
between 185 and 235 (C-term)
Human
WB, IHC
residues 22-180 (ECD)
Human
WB, IP, IHC, ICC
residues 29-502 (ECD)
Human
WB, IP, IHC, ICC
residues 19-229 (ECD)
Human
WB, IP, IHC, ICC
between 125 and 175
Human
WB, IP, IHC, ICC, IHC-IF, mIF
between 275 and 325
Human, Mouse
WB, IP, IHC, ICC
between 150 and 200
Human
WB, IP, IHC, ICC, IHC-IF
between 191 and 241 (C-term)
Human
WB, IHC, ICC, IHC-IF, mIF
residues 19-247 (mature protein)
Human
WB, IP, IHC, ICC, IHC-IF, mIF
between 500 and 525 (C-term)
Human
WB, IP, IHC, ICC, IHC-IF
residues 23-450 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF
residues 29-216 (ECD)
Human
IHC
residues 24-164 (ECD)
Human
WB, IP, IHC, ICC
between 1 and 50
Human
WB, IP
between 200 and 250
Human, Mouse
WB, IP, IHC, ICC
between 1 and 50
Human, Mouse
WB, IP, IHC, ICC
between 744 and 794 (C-term)
Human
WB, IP, IHC, ICC
between 485 and 535 (C-term)
Human
WB, IHC, IHC-IF
between 194 and 244 (C-term)
Human
WB, IHC, ICC, IHC-IF
residues 22-201 (ECD)
Human
WB, IP, IHC, ICC, IHC-IF, F
between 250 and 311 (C-term)
Human, Mouse
WB, IP, IHC
between 276 and 326
Human, Mouse
IHC
Between 276 and 326
Human
IP
Between 75 and 125
Human
WB, IP
Between 114 and 164
Human
WB, IP
Between 114 and 164
Human
WB
Between 50 and 100
Human
WB, IP, IHC
Between 157 and 207
Human
IHC, IHC-IF, F
A 13 amino acid synthetic peptide from the C-terminal cytoplasmic domain of alpha chain of human CD8 molecule
Human
WB, IP
Between 286 and 336
Human
WB, IHC
between 150 and 200
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-044 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-044 and A500-017A
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-018A and A500-017A
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-020 and A700-034
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A500-018A, A700-021 and A700-020
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A700-022, A700-044, A500-019A, A700-021 and A700-080
Human
IHC-IF, mIF
Includes: 1 each of A700-044, A500-019A, A500-020A, A700-015 and A700-034
Human
IHC-IF, mIF
Includes: 1 each of A700-016, A500-019A, A700-044, A700-015, A700-027 and A700-034
Human
WB, IP, IHC
between 744 and 794

(*) Further Reading:

  • Bai, R., Lv, Z., Xu, D. et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res8, 34 (2020).
  • Buchan, S.L., Rogel, A., Al-Shamkhani, A., The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131 (1): 39–48 (2018).